Tradestie Institutional Equity Comparison Engine

NERV vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NERV trades at 11.2x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, NERV sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
NERV 11.2x vs MNOV 8.5x Fwd P/E
Growth & Margin Winner MNOV
Op Margin 0.0% vs -1232.2% ยท YoY +0.0% vs +12.4%
Momentum & Technical Winner MNOV
1Y -53.5% vs -8.4% ยท 52W Pos 1% vs 3%
Options & Structure Winner MNOV
BREAKDOWN (100th %ile IV) vs UNCLASSIFIED (50th %ile IV)
NERV NASDAQ
Minerva Neurosciences, Inc
Pharmaceutical Preparations
$2.00
-5.66% 1D
Market Cap $105.7M
1M Return -16.67%
1Y Return -53.49%
Forward P/E 11.2x
Unified AI Score
43.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NERV -53.49% MNOV -8.39% Spread: +45.1 pp (MNOV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NERV TTM Op. Margin: 0.0% MNOV TTM Op. Margin: -1232.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NERV vs MNOV. Trailing 12-month operating profitability (NERV 0.0% vs MNOV -1232.2%) and valuation multiples (NERV 11.2x vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NERV (2) vs MNOV (7)
Institutional Metric NERV MNOV Criterion Row Winner
Market Capitalization Scale $105.7M $65.1M Larger Scale NERV
Trailing P/E Ratio Valuation 11.2x 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation 11.2x 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth +0.0% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability 0.0% -1232.2% Higher Margin NERV
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -675.1% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 1% ($2โ€“$9) 3% ($1โ€“$4) Stronger Trend MNOV
Beta / 30D Volatility Risk Regime 1.63ฮฒ ยท 76% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NERV vs MNOV Buy Guide
NERV BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live NERV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NERV nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.